drugset / Trial / NCT04814498

Drug-Drug Interaction (DDI) Study in Healthy Volunteers

NCT04814498

Phase 1 Completed 16 enrolled Blade Therapeutics
NaSequentialOpen-labelTreatment

Summary

A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of BLD-0409 on the Single Dose Pharmacokinetics of a Cocktail of Probe Substrates for CYP450 Enzymes in Healthy Volunteers

Timeline

Start
2021-05-03
Primary completion
2021-09-17
Completion
2022-01-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 20 mg
Subject Caffeine Small molecule 50 mg
Subject Cudetaxestat Small molecule
Subject Dextromethorphan Unknown 10 mg
Subject Flurbiprofen Small molecule 10 mg
Subject Midazolam Small molecule 1 mg
Subject Omeprazole Other / unclassified 10 mg

Indications

No indication recorded.